Cytoplasmic residues of phospholamban interact with membrane surfaces in the presence of SERCA: A new role for phospholipids in the regulation of cardiac calcium cycling?  by Hughes, Eleri et al.
Biochimica et Biophysica Acta 1788 (2009) 559–566
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamemCytoplasmic residues of phospholamban interact with membrane surfaces in the
presence of SERCA: A new role for phospholipids in the regulation of cardiac
calcium cycling?
Eleri Hughes, Jonathan C. Clayton, David A. Middleton ⁎
School of Biological Sciences, University of Liverpool, L69 7ZB Liverpool, UKAbbreviations: SERCA, sarco(endo)plasmic reticulum
lamban; NMR, nuclear magnetic resonance; ITC, isother
electron paramagnetic resonance; SR, sarcoplasmic reti
null-cysteine variant of PLB mutated as C36A C41A C
cytoplasmic residues 1–23 of phospholamban; DOPC, L-α
DOPE, L-α-dioleoylphosphatidylethanolamine; DOPS, L-
DOPG, L-α-dioleoylphosphatidylglycerol; DMPC, L-α-di
MAS, magic angle spinning; PI, phosphatidylinositol; Δν
⁎ Corresponding author. Tel.: +44 151 7954457; fax: +
E-mail address: d.a.middleton@liverpool.ac.uk (D.A.
0005-2736/$ – see front matter © 2008 Elsevier B.V. Al
doi:10.1016/j.bbamem.2008.10.029a b s t r a c ta r t i c l e i n f oArticle history: The 52-amino acid transme
Received 22 August 2008
Received in revised form 10 October 2008
Accepted 29 October 2008





Isothermal titration calorimetrymbrane protein phospholamban (PLB) regulates calcium cycling in cardiac cells
by forming a complex with the sarco(endo)plasmic reticulum calcium ATPase (SERCA) and reversibly
diminishing the rate of calcium uptake by the sarcoplasmic reticulum. The N-terminal cytoplasmic domain of
PLB interacts with the cytoplasmic domain of SERCA, but, in the absence of the enzyme, can also associate
with the surface of anionic phospholipid membranes. This work investigates whether the cytoplasmic
domain of PLB can also associate with membrane surfaces in the presence of SERCA, and whether such
interactions could inﬂuence the regulation of the enzyme. It is shown using solid-state NMR and isothermal
titration calorimetry (ITC) that an N-terminally acetylated peptide representing the ﬁrst 23 N-terminal amino
acids of PLB (PLB1–23) interacts with membranes composed of zwitterionic phosphatidylcholine (PC) and
anionic phosphatidylglycerol (PG) lipids in the absence and presence of SERCA. Functional measurements of
SERCA in sarcoplasmic reticulum (SR) vesicles, planar SR membranes and reconstituted into PC/PG
membranes indicate that PLB1–23 lowers the maximal rate of ATP hydrolysis by acting at the cytoplasmic face
of the enzyme. A small, but statistically signiﬁcant, reduction in the inhibitory effect of the peptide is
observed for SERCA reconstituted into PC/PG membranes compared to SERCA in membranes of PC alone. It is
suggested that interactions between the cytoplasmic domain of PLB and negatively charged phospholipids
might play a role in moderating the regulation of SERCA, with implications for cardiac muscle contractility.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Muscle contraction and relaxation involves a cyclical movement of
calcium ions into and out of the cytoplasm of each muscle cell. The
major route of calcium removal from the cytoplasm of muscle cells is
via the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) to the
lumen of the sarcoplasmic reticulum (SR). The cardiac isoform of
SERCA (SERCA2a) is regulated by the transmembrane protein
phospholamban (PLB) [1], which associates directly with the enzyme
and stabilises it in Ca2+ free form. PLB exists predominantly as a
homopentamer in the SR membrane, but it is believed that the
monomeric form of the protein is the principal inhibitory species [2].Ca2+-ATPase; PLB, phospho-
mal titration calorimetry; EPR,
culum; AAA-PLB, a full-length,
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l rights reserved.At low cytoplasmic calcium concentrations unphosphorylated PLB
diminishes the apparent afﬁnity of SERCA for calcium [3], which
decreases both calcium transport and ATPase rates at physiological
calcium concentrations. Inhibition of SERCA is relieved at elevated
calcium levels [4] or after phosphorylation of PLB at Ser-16 and/or Thr-
17 in response to β-adrenergic stimulation, which increases calcium
uptake by the SR that is necessary for muscle relaxation [5]. The effect
of PLB on the maximal activity (Vmax) of SERCA is unclear, as some
studies have reported no signiﬁcant effect [6] whereas others show a
clear reduction [7,8]. Conclusions about the effects of PLB on Vmax in
co-reconstituted or co-expression systems are unreliable because the
yields of active SERCA recovered can vary substantially from
preparation to preparation even in the absence of PLB. Calcium
dependent activity curves for SERCA in the presence and absence of
PLB are therefore usually normalised to Vmax so as to observe the
afﬁnity of SERCA for calcium, which is a more reliable measure of the
regulatory effect of PLB.
PLB appears to regulate SERCA in part through interactions within
the membrane and studies on truncated PLB analogues showed that
the transmembrane region alone is sufﬁcient to lower the afﬁnity of
SERCA for calcium [9,10]. Less clear is the role of the cytoplasmic
domain of PLB, which is N-terminally acetylated in cardiac SR [11].
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that several residues in this region are essential for the regulatory
interaction with SERCA [12–14] but do not conﬁrm that this region
alone is inhibitory. Studies on the effects of water soluble peptides
representing the N-terminal residues of the PLB cytoplasmic domain
have been apparently contradictory and inconclusive. Sasaki and co-
workers showed that a peptide PLB1–31, comprising the ﬁrst 31 N-
terminal amino acids of PLB, lowers maximal activity by 40% when
present in a 330-fold molar excess over the enzyme and Lee et al.
showed that the shorter peptide PLB1–25 has a similar effect on Vmax
[15,16]. By contrast, several other studies have found that peptides
encompassing all or some of the ﬁrst 31 residues of PLB have no effect
at all on SERCA activity [17–19]. Lee and co-workers have shown that
the maximal activity of SERCA is lowered by PLB1–25 only when the
peptide is N-terminally acetylated [20] and a recent study from this
laboratory has shown that N-terminally acetylated PLB1–23 inhibits
calcium uptake by SR vesicles at peptide concentrations of less than
100 μM [21].
NMR and EPR data show evidence for a dynamic equilibrium in the
PLB cytoplasmic domain between a tense state that is ordered and a
relaxed state that is dynamically disordered and extended [22]. SERCA
perturbs the dynamic equilibrium of the PLB cytoplasmic domain,
causing sites around Ala24-Gln26 of PLB to act as a focus for a
conformational and/or orientational transition [23]. Further EPR
studies of a monomeric mutant of PLB spin labelled at residue 11
showed that the spin label was quite rotationally mobile in the
absence of SERCA, but became more restricted in the presence of
SERCA [24]. From these observations, it has been proposed that the
cytoplasmic domain of PLB associates with the lipid surface, and that
associationwith SERCA induces a major conformational change in PLB
inwhich the cytoplasmic domain is drawn away from the lipid surface
by SERCA [22,24]. This theory is supported by the observation that
PLB1–23 interacts with membrane surfaces in the absence of SERCA,
with a preference for negatively charged lipid head groups [25].
This study examines whether N-terminally acetylated PLB1–23,
used as a proxy for the PLB cytoplasmic domain, can interact with the
surface of membranes containing the lipids phosphatidylcholine (PC)
and anionic phosphatidylglycerol (PG) in the presence of SERCA. We
also investigate the effect of the peptide on SERCA activity in SR
vesicles, planar nativemembranes and reconstituted into deﬁned lipid
bilayers. The results provide further evidence that the cytoplasmic
domain of PLB lowers the maximal activity of SERCA and suggest that
the inhibitory effect is modulated by interactions between PLB1–23 and
negatively charged lipid head groups. The results suggest that PLB-
membrane interactions may play a physiological role by moderating
the uptake of calcium by the sarcoplasmic reticulum.
2. Materials and methods
2.1. Materials
Synthetic NAc-PLB1–23 (N95% pure) was purchased from Peptide
Protein Research Ltd (U.K.). All other chemicals were purchased from
Sigma.
2.2. Preparation of SR microsomes and further puriﬁcation of SERCA1a
The fast-twitch skeletal muscle ATPase (SERCA1), rather than the
cardiac isoform, was examined in this work as sufﬁcient quantities of
enzyme could be obtained for analysis and previous studies have
shown that the functional properties of SERCA1 and its inhibition by
PLB are similar to those of SERCA2a [6,12,26]. SERCA1a was puriﬁed
from fast-twitch rabbit skeletal muscle according to amethod adapted
from East and Lee [27]. First, SRmicrosomeswere prepared from100 g
muscle tissue by differential centrifugation. A fraction of the intact SR
vesicles was retained for calcium uptake measurements and theremainder was treated with sodium cholate and subjected to density
gradient centrifugation to yield membranes containing approximately
100 mg of ∼90% pure SERCA1a as characterized by SDS-PAGE on a 10%
resolving gel. Protein concentrations were calculated using an
adaptation of the Lowry method [28]. Puriﬁed SERCA was reconsti-
tuted into DOPC, DMPC-d4/DOPG and DOPC/DOPG membranes using
an adaptation of methods described previously [29–31].
2.3. Activity measurements
Speciﬁc Ca2+-ATPase activity was quantiﬁed as the amount of
inorganic phosphate (Pi) liberated upon ATP hydrolysis at 37 °C, as
described previously [31]. Free calciumwas calculated from a method
adapted from Tatulian et al. [32]. Membranous Na+/K+-ATPase was
puriﬁed from pig kidney microsomal membranes and enzymatic
activities and protein concentrations were determined as described
previously [33,34].
2.4. Preparation of vesicles
Small unilamellar vesicles (SUVs) were prepared from dimyris-
toylphosphatidylcholine (DMPC) and dioleoylphosphatidylglycerol
(DOPG) or from DMPC and dioleoylphosphatidylcholine (DOPC),
with the PC lipids in a 2-fold molar excess in both cases. Lipids
were prepared in chloroform and then dried under argon and high
vacuum, before resuspension in 10 mM Tris, 1 mM EDTA, pH 7.4.
Sonication was carried out on ice, using a Dawe Ultrasonic probe
sonicator at 50% duty cycle for 1–2 min, output control 5, to promote
formation of SUVs.
2.5. Solid-state NMR
Measurements were performed using a Bruker Avance 400
spectrometer operating at a magnetic ﬁeld of 9.3 T. The experimental
temperature was 37 °C. Samples were conﬁned within the centre of a
4 mm external diameter zirconium rotor. Wide line 2H NMR spectra of
membranes containing DMPC-d4 were obtained using a double-tuned
magic-angle spinning probe without sample spinning. Spectra were
recorded as a result of accumulating 60,000 transients with a 1-s
recycle delay. The quadrupole echo sequence (90x–τ–90y–τ– acquisi-
tion) [35] was used with a 90° pulse length of 4 μs and inter-pulse
delay τ of 22 μs. For 31P magic-angle spinning (MAS) NMR
experiments, samples were spun at 4 kHz, maintained automatically
to within ±1 Hz. A 31P 90° excitation pulse length of 4.0 μs was
followed by sampling of the free-induction decay with simultaneous
proton decoupling at a ﬁeld of 65 kHz. Each spectrumwas the result of
accumulating 4096 transients with a 2-s recycle delay between scans,
giving a total acquisition time of 2.3 h per spectrum.
2.6. Isothermal titration calorimetry (ITC)
Heat ﬂow resulting from peptide binding to lipid vesicles was
measured using a high-sensitivity VP-ITC MicroCalorimeter (MicroCal
LLC, Northampton, MA), with a reaction cell volume of 1.4448 ml and
total injection volume of 279.5 μl. All experiments were performed at
25 °C, at a power reference setting of 15 μcal/s with stirring at 307 rpm.
Prior to use all solutions were degassed under vacuum. Data analysis
was carried out using the Origin v.7 software developed for MicroCal.
Experimental conditions were designed following established proto-
cols [36,37].
The reaction cell contained a 25 μM solution of PLB1–23, in 10 mM
Tris; 1 mM EDTA, pH 7.4. A 10 mM suspension of 2:1 DMPC/DOPG or
DMPC/DOPC SUVs was prepared in the same buffer and injected via
the syringe. The reference cell contained dH2O. SUVs were titrated in
to the peptide solution at intervals of 10 min in 10 μl aliquots,
following an initial 3 μl aliquot, and continuing until the syringe was
Fig. 1. ITC experiment investigating the relative afﬁnity for membrane binding of
PLB1– 23 to lipidswith either a net negative or neutral charge. (a) Titration of 10mMSUVs
of DMPC/DOPG into 25 μM PLB1–23. (b) Curve ﬁt of integrated peaks following titration
of DMPC/DOPG (ﬁlled circles) and DMPC/DOPC (open circles) SUVs into PLB1–23.
Fig. 2. NMR experiments to examine the interaction of PLB1–23 with phospholipid
headgroups in membranes containing SERCA. (a) Wide line 2H NMR spectra of DMPC-
d4/DOPG membranes alone (top), with SERCA at a lipid/protein ratio of 160:1 (middle)
and with SERCA and PLB1–23 at a lipid/peptide/SERCA molar ratio of 160:8:1 (bottom).
(b) A 31P MAS NMR experiment to detect the association of PLB1–23 with membrane
phospholipids in the absence and presence of SERCA1. Spectra are shown for (from top
to bottom): 2:1 DMPC/DOPG membranes alone; DMPC/DOPC membranes with PLB1–23
at a l/p ratio of 20:1; DMPC/DOPG membranes with PLB1–23; SERCA at a lipid/PLB1–23/
SERCA ratio of 1000:50:1; and 15:4:1 DOPC/DOPE/DOPSmembranes alone. (c) The peak
widths at half height (Δν1/2) for DMPC and DOPG in the absence and presence of PLB1–23
are shown at different lipid/SERCA molar ratios.
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recommended in theMicroCal manual. Each injection generates a heat
of reaction hi, which was determined by integration of the individual
peaks from the heat ﬂow trace. The heat of dilution hd,i, was
determined in controls experiments whereby lipid vesicles were
titrated in to buffer solution. Subtraction of hd,i values from
experimental values allows the determination of heat ﬂow resulting
from peptide binding to lipid.
3. Results
3.1. PLB cytoplasmic domain associates with a higher afﬁnity to
anionic lipids
ITC was used to compare the afﬁnity of PLB1–23 for membranes of
different composition and surface charge (DMPC/DOPC and DMPC/
DOPG, with DMPC in a 2-fold molar excess). The two membrane
samples have an identical mixture of hydrocarbon chains but differ in
the polar headgroups. Titration of DMPC/DOPG SUVs into a 25 μM
solution of peptide at 25 °C generated an exothermic binding reaction
(Fig. 1). The small enthalpy changes occurring with each titration
demonstrate that membrane binding is rather weak and incomplete
even after 27 titrations of 10 μl aliquots. It is thus not possible to
determine the total binding enthalpy or a complete binding isotherm,
but apparent saturation occurred at a molar ratio in excess of 80:1
lipid/peptide, with half maximal binding at a lipid/peptide molar ratio
of ∼25:1. In contrast, titration with zwitterionic lipids (DMPC/DOPC),
results in no observable heat of reaction, indicating a lack of detectable
peptide binding to neutral membranes. These results follow the trend
ofmembrane afﬁnitymeasurements on PLB1–23 [25] and are consistent
with a relationship between the membrane afﬁnity of PLB1–23 and the
surface charge density of the membrane in the absence of SERCA.3.2. PLB cytoplasmic domain associates with anionic lipids in the
presence of SERCA
Our previous work investigated whether the cytoplasmic domain
of PLB interacts with negatively charged membrane surfaces in the
absence of SERCA [25]. Membrane surface interactions were detected
by observing the 2H NMR line shapes for multilamellar vesicles of
DOPG and a 2-fold molar excess of DMPC with deuterons at the
choline α and β positions (DMPC-d4). Addition of PLB1–23 to the
membranes decreased the splitting for theα-deuterons and increased
the β-deuteron splitting, indicating that the peptide interacts with the
membrane surface and perturbs the orientation of the choline head-
group. Here further experiments investigate whether PLB1–23 can also
associate with the phospholipids of membranes containing SERCA as
such interactions may be physiologically relevant.
The 2H NMR spectrum of pure DMPC-d4/DOPG membranes
exhibits two sets of Pake doublets with quadrupole splittings (ΔνQ)
of ∼9.3 kHz for the α-deuterons and ∼1.5 kHz for the β-deuterons of
DMPC-d4 (Fig. 2a). In membranes containing SERCA the α-deuteron
splitting is reduced to 5.7 kHz and the β-deuteron splitting increased
to 2.7 kHz. The spectrum also has a narrow central component,
possibly from smaller vesicular structures or micelles. The change in
Fig. 3. Calcium-dependent ATPase activity of SERCA1 co-reconstituted with AAA-PLB
into DOPC membranes at lipid:AAA-PLB:SERCA1 molar ratios of 500:0:1 (squares) and
500:20:1 (triangles). The curves are normalised to Vmax for each sample. The maximal
activity for SERCA in the absence of AAA-PLB was 4.67 mmol/mg/min.
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dynamics and/or orientation of the choline headgroups. The spectrum
broadens after the addition of PLB1–23 to a lipid to peptide molar ratio
of 20:1, with the inner splitting increasing to 3.1 kHz and the outer
splitting increasing to 6.5 kHz. These changes are consistent with a
further structural rearrangement of the choline headgroups, caused by
their association with the peptide. This could occur if the peptide
diffuses laterally at the membrane surface or if the peptide associates
with speciﬁc lipid components and organises them into clusters.
Magic angle spinning (MAS) 31P NMR was used to observe
interactions between PLB1–23 and individual lipid components of
membranes containing SERCA, by exploiting the intrinsic NMR signal
from the lipid phosphate head groups. In mixed lipid membranes the
association of peptideswith the head-groups of speciﬁc lipid species can
be detected from changes in 31P linewidths at half height (Δν1/2) for the
different lipids, which generally broaden as a result of motional
restriction by the peptide. Spectra were obtained for membranes at
different lipid/SERCA ratios in absence and presence of PLB1–23.
Experiments were carried out with the DMPC/DOPGmembrane system
used in the ITC experiments and in our earlierwork [25]. Spectra of these
membranes alone or in the presence of SERCA and PLB1–23 show two
clearly resolved peaks for the two lipid components (Fig. 2b, top three
spectra). We also examined the effects of PLB1–23 on membranes
composed of DOPC, dioleoylphosphatidylethanolamine (DOPE) and
anionic dioleoylphosphatidylserine (DOPS), which emulate the compo-
sition of SR membranes (Fig. 2b, bottom). Unfortunately, none of the
individual lipid species could be resolved and so the experiments were
aborted. The line widths for the DMPC/DOPG membranes generally
broadened as the SERCA/lipid ratio increased, consistent with the
laterally diffusing lipids being restrained at the transmembrane interface
with SERCA (Fig. 2c). In the presence of PLB1–23 at a 20:1 lipid/peptide
molar ratio, the line widths for DMPC at the different SERCA
concentrations are not signiﬁcantly different to the line widths in the
absence of the peptide. By contrast, at all SERCA concentrations the peak
for DOPG ismuch broader in the presence of PLB1–23 than in the absence
of the peptide. The selective broadening suggests that the peptide
diffuses across themembrane surface and associates preferentially with
theDOPG head groups, thereby restraining the anionic lipids even in the
presence of SERCA. The 2Hand 31PNMRmeasurements together conﬁrm
that PLB1–23 associates with lipid headgroups in the presence of SERCA.
3.3. Inhibition of SERCA by null-cysteine PLB
SERCAwas reconstituted into dioleoylphosphatidylcholine (DOPC)
membranes alone at a lipid/SERCA molar ratio of 500:1, or together
with a triple Cys-Alamutant of PLB (AAA-PLB). The triplemutant of PLB
was used as it remains predominantly in the monomeric, SERCA-
regulating form [2]. The activity of SERCA alone or in the presence of a
20-fold molar excess of AAA-PLB was measured by observing the
amount of inorganic phosphate (Pi) liberated upon hydrolysis of ATP.
ATPase activity is coupled to the transport of Ca2+ by the enzyme. The
normalised calcium concentration-dependent speciﬁc activity curve
for SERCA in DOPC is shown in Fig. 3. In the presence of PLB the curve
shifts to the right signifying a reduction in the afﬁnity of the enzyme for
calcium, as reported elsewhere [9,10]. Maximal SERCA activity (Vmax)
also appeared to be depressed in the presence of AAA-PLB (not shown),
but as the recoveryof active enzyme can vary signiﬁcantly fromsample
to sample the effects on Vmax cannot be conﬁdently attributed to the
inhibition of SERCA by AAA-PLB. The role of the cytoplasmic domain in
modulating the rate of ATP hydrolysis was investigated further with
functional measurements on SERCA in the presence of PLB1–23.
3.4. Inhibition of SERCA by PLB1–23
N-terminally acetylated PLB1–23 was previously found to reduce
the maximal rate of calcium transport by SERCA (at 1 μM Ca2+) byinteracting with the enzyme at the cytoplasmic face, which is
accessible to the cytoplasmic domain of full-length PLB in vivo [21].
Consistent with this observation, PLB1–23 here inhibited ATPase
activity by SR vesicles at 1 μM Ca2+. The IC50 for ATPase inhibition in
SRwas approximately 50 μM, although the enzyme remains about 40%
active at a peptide concentration of 100 μM (Fig. 4a). These results
reﬂect those of a similar study by Lee and co-workers [15], who
showed that PLB1–25 inhibits calcium uptake by 40% at a peptide
concentration of 50 μM, but disagree with the ﬁndings of Jones and
Field who did not observe any effect of PLB2–25 on calcium uptake by
SR vesicles from atrial tumor cells over a 35 min period [18].
The IC50 for inhibition of ATPase activity by SERCA in planar
membranes occurs at peptide concentrations between 20 μM and
50 μM, with maximal inhibition being about 60% at a peptide
concentration of 100 μM (Fig. 4b). PLB1–23 does not affect the ATPase
activity of Na+/K+-ATPase at peptide concentrations of 50 μM and
100 μM (Fig. 4b), consistent with SERCA having an inhibitory binding
site for the peptide (and, by implication, the PLB cytoplasmic domain)
that is absent in other homologous ATPases. A calcium concentration
curve of planar SERCA membranes in the presence and absence of
50 μMPLB1–23 demonstrates that the peptide reduces the enzyme Vmax
by about 25% (Fig. 4c). Themaximal speciﬁc activity of SERCA in planar
membranes is reduced from 2.2 μmol Pi/mg/min to 1.6 μmol/mg/min.
3.5. Effect of membrane composition on SERCA inhibition by PLB1–23
Next it was investigated whether the propensity of PLB1–23 to
associate with phospholipid membranes inﬂuences the availability of
the peptide to interact with SERCA and regulate enzyme function. The
results would suggest whether or not the association of the PLB
cytoplasmic domain with SERCA is modulated by the SR membrane
environment. This hypothesis was tested by measuring the effect of
PLB1–23 on the activity of SERCA reconstituted into DOPC membranes
with neutral surface charge or DOPC/DOPG membranes with negative
surface charge, at a lipid/SERCA molar ratio of 160:1 in both cases. In a
200 μl reaction medium containing 5 μg enzyme, a 50 μM concentra-
tion of PLB1–23 corresponds approximately to an equimolar peptide/
lipid ratio. The ITC results (Fig. 1) suggest that at this ratio a minor
fraction of peptide is likely to be bound to the DOPC/DOPG
membranes and so any reduction in the inhibition of SERCA compared
to that in DOPC is expected to be small. We therefore examined SERCA
ATPase activity in the presence of 25–100 μM PLB1–23 for three
individually reconstituted DOPC/DOPG and three individually recon-
stituted DOPC samples, each sample measured in triplicate, to observe
any small but statistically signiﬁcant differences in inhibition. The
Fig. 5. The effect of PLB1–23 upon the rate of ATP hydrolysis by SERCA1 in different
membrane environments. Rates of ATP hydrolysis (at a free Ca2+ concentration of 1 μM)
were measured at 37 °C over a range of PLB1–23 concentrations, for 5 μg SERCA in DOPC
membranes (squares) or DOPC/DOPG membranes (circles) at a lipid/SERCA molar ratio
of 160:1. The maximal ATPase activity of SERCA in the absence of peptide for DOPC and
DOPC/DOPG membranes was 2.1 μmol/mg/min and 1.7 μmol/mg/min respectively.
Fig. 4. Analysis of the effects of PLB1–23 on SERCA activity. (a) Dose–response curve of
ATPase activity of SERCA in SR vesicles at concentrations of up to 150 μM PLB1–23.
Activities were measured 3 min after initiation of the reaction by the addition of ATP,
with data expressed as a percentage of maximal hydrolytic activity in the absence of
peptide (2.6 μmol/mg/min). (b) A dose–response curve of the ATPase activities of
puriﬁed SERCA (squares) and puriﬁed Na,K-ATPase (circles) in planar membranes at
concentrations of PLB1–23 of up to 100 μM. (c) A calcium curve of the ATPase activity in
planar SERCA membranes in the presence (circles) and absence (squares) of 50 μM
PLB1–23. Data are expressed as a percentage of maximal hydrolytic activity in the
absence of peptide (2.2 μmol/mg/min).
563E. Hughes et al. / Biochimica et Biophysica Acta 1788 (2009) 559–566highest PLB1–23 concentration (100 μM), which corresponds to a
peptide/lipid molar ratio of 2:1, inhibits the ATPase activity of both
membranes equally by ∼35% (Fig. 5). The lack of distinction at this
peptide concentration may be attributed to the large excess of peptide
not associated with the membrane. At peptide concentrations of
25 μM and 50 μM, however, there is a signiﬁcant difference in the
inhibition of ATPase activity in the twomembrane environments, with
inhibition being ∼10% greater in the DOPC membranes than in the
DOPC/DOPG membranes. Taken together with ITC data, these results
indicate that interactions between PLB1–23 and membrane surfaces,which occur in the presence of anionic phospholipids, can reduce the
availability of the peptide for interacting with the cytoplasmic domain
of SERCA. A similar mechanism could be envisaged for the cytoplasmic
domain of full length PLB in the SR membrane as will be discussed.
4. Discussion
4.1. The inhibitory effect of the PLB cytoplasmic domain
Much is now understood about how PLB regulates SERCA in the SR
membrane, but the precise role played by the 25 or so residues in the
cytoplasmic domain of PLB remains a matter of debate. Amino acids
within this region associate with SERCA [12–14], but it is not clear
whether they act simply to anchor the peptide to its physiological
target or whether they contribute directly to SERCA inhibition. It is
generally agreed that the PLB cytoplasmic domain is not required for
the protein to lower the calcium afﬁnity of SERCA, but how the
maximal enzyme activity is affected by the cytoplasmic domain, or,
indeed, by full-length PLB, has yet to be conﬁrmed. Hughes and co-
workers [7] found that reconstitution of SERCA with a monomeric
mutant of full-length PLB lowered both Vmax and the apparent afﬁnity
of the enzyme for calcium, but reconstitution of SERCAwith a peptide
representing the transmembrane domain of PLB diminished apparent
calcium afﬁnity but not maximal activity. Their results imply that the
cytoplasmic domain of PLB may be responsible for lowering Vmax, but
alone are not conﬁrmatory.
Measurements of SERCA activity in the presence of water-soluble
peptides representing the PLB cytoplasmic domain would seemingly
provide a convenient means of answering this long standing question,
but results to date have been inconclusive. It is shown here that the
peptide PLB1–23 decreases Vmax for ATPase activity of SERCA in SR
vesicles, in planar SERCA membranes and reconstituted into deﬁned
lipid membranes, but does not lower the afﬁnity of SERCA for calcium.
On the other hand, full-length PLB lowers the afﬁnity of SERCA for
calcium [9,10], suggesting that the cytoplasmic and transmembrane
domains act in concert to regulate enzyme function.
Our results for the functional effect of PLB1–23 agree closely with
the effects seen for similar peptides by Tada et al. (PLB1–31) and also by
Lee et al. who found that the peptide PLB1–25 lowers Vmax without
affecting calcium afﬁnity, and shifts the conformational equilibrium of
SERCA toward the E1 form. Our results apparently disagree with those
of Karim et al. (PLB1–25K) and Stokes et al. (PLB1–31), who report that
the peptides have no effect on SERCA activity. In the work by the
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concentration of 7 μM. Here, similar concentrations of PLB1–23 also had
little or no effect upon ATPase activity, with signiﬁcant effects
observed only at peptide concentrations higher than 20 μM (Fig. 4a
and b). In this case, the discrepancy may thus be related simply to
differences in peptide concentration. This explanation could also
account for the apparent disagreement with the work from Karim and
colleagues, who saw no effect of PLB1–25K when the peptide was
present in 10-fold excess over SERCA. In their work, ATPase activity
was measured at enzyme concentrations of up to 0.6 μg/200 μl, so the
actual concentration of PLB1–25K was no higher than 0.3 μM. Jones and
Field, however, saw no effect of the peptide PLB2–25 on calcium uptake
by mouse SR ventricular SR vesicles even at peptide concentrations as
high as 440 μM [18]. In cardiac myocytes PLB is acetylated
posttranslationally at the N-terminal methionine, and Lee and co-
workers have shown that acetylation of PLB1–25 is critical for lowering
the maximal activity of SERCA [20], although acetylated full-length
PLB does not lower the afﬁnity of the enzyme for calcium [38]. In the
study by Jones and Field it appears that PLB2–25 was not modiﬁed in
this way, which might explain the inconsistency with our results,
since here PLB1–23 was acetylated.
4.2. Physiological relevance and signiﬁcance
Our work does not offer conclusive evidence that the inhibitory
interaction between PLB1–23 and SERCA reﬂects the physiological
interaction between SERCA and the PLB cytoplasmic domain in SR
membranes, but there are positive indications that this may be the
case. The inhibitory interaction between PLB1–23 and SERCA must
occur at the physiologically relevant (i.e., cytoplasmic) face of the
enzyme to be able to lower ATPase activity and calcium uptake by SR
vesicles. Moreover, the peptide does not affect Na+/K+-ATPase activity,
suggesting that SERCA has a speciﬁc recognition site for the peptide
that is not present in homologous ATPases. The peptide PLM38–72,
representing the cytoplasmic domain of the Na+/K+-ATPase-regulating
protein phospholemman, has no effect on the activity of SERCA at aFig. 6. Schematic of the PLB–SERCA interaction reconciling the structure, dynamics and me
convenience. The cytoplasmic domain of PLB is highly dynamic and its orientational distrib
darker blue shades. In the absence of SERCA, the PLB cytoplasmic domain interacts transien
than for neutral surfaces (a, right). In the presence of SERCA (right) the equilibrium distributi
cytoplasmic domain of SERCA. In neutral membranes the cytoplasmic domain of PLB is ass
equilibrium is shifted less toward the SERCA bound orientation and contact with the membpeptide concentration of 100 μM [21], which indicates that SERCA has
some selectivity for PLB1–23.
The inhibitory effect of PLB1–23 is rather weak and high peptide
concentrations (50–80 μM) were needed to achieve 50% reduction in
activity. This concentration represents a ∼200-fold excess of PLB1–23
over the enzyme, whereas full-length, membrane-embedded PLB
affects SERCA activity when in a 20-fold excess over the enzyme
(Fig. 3). It is erroneous to compare directly the inhibitory capacity of a
water soluble peptide, which diffuses in three dimensions, to the
effect of the same sequence when attached to the transmembrane
domain and diffusing in two dimensions. There is a higher probability
of productive collisions occurring between PLB and SERCA when both
proteins are embedded in a membrane than when one or both
partners are in the aqueous phase. This argument can be qualiﬁed
with reference to the hypothesis proposed by Kholodenko et al. to
explainwhy signalling proteins should be recruited to cell membranes
[39]: “The dissociation constant Kd required for a certain degree of
association of two membrane-linked proteins exceeds that required
for the same degree of association of two cytosolic proteins by the
ratio VC/VM”, where in this context VC is the volume of the aqueous
medium and VM is the membrane surface volume accessible to the
cytoplasmic domain of PLB. For the conditions of our functional
measurements, the lower limit of VC/VM is ∼40 and so, by anchoring
PLB1–23 to the membrane, the concentration required to achieve the
same inhibitory effect as the aqueous peptide would be lowered by
approximately the same factor. This assumes that the membrane
anchor is inert, but the fact that the transmembrane domain of PLB
alone associates with SERCA and has an effect upon enzyme function
will also enhance the inhibitory effect of the cytoplasmic domain
compared to that of PLB1–23 in solution.
NMR studies of PLB and PLB1–23 in lipid bilayers indicate that the
cytoplasmic domain associates with the membrane surface [25] and
recent opinion is that the overall structure of the pentameric assembly
in lipid bilayers has a pinwheel-like appearance with the cytoplasmic
domain parallel with the plane of the membrane [40]. These recent
results raise the possibility that the structural and orientationalmbrane afﬁnity of the cytoplasmic domain. The monomeric state of PLB is shown for
ution is denoted here by the shade, the dynamic equilibrium being biased toward the
tly with lipid head groups, with higher afﬁnity for negative membrane surfaces (b, left)
on of PLB orientations is displaced toward an upright position allowing contact with the
ociated predominantly with SERCA (a, left) but in negatively charged membranes the
rane surface still occurs (b, left). The representation of SERCA is adapted from Ref. [53].
565E. Hughes et al. / Biochimica et Biophysica Acta 1788 (2009) 559–566equilibrium of the PLB cytoplasmic domain is inﬂuenced by lipid
membrane composition and surface charge. Such behaviour is
physiologically relevant, because the cytoplasmic face of the SR
membrane contains small amounts of the anionic phospholipids
phosphatidylserine (PS) and phosphatidylinositol (PI). The structure
likely reﬂects a weighted-average of the PLB cytoplasmic domain
orientation, as solid-state NMR measurements have shown it to be
highly dynamic and sampling different conformations and/or orienta-
tions [41,42].
Here, studies of the effects of PLB1–23 on the activity of SERCA
reconstituted into membranes of different lipid compositions suggest
that the membrane surface charge could moderate slightly the
inhibition of SERCA by PLB. Experimental and in silico methods have
elucidated some of the structural features of the SERCA-PLB complex
and our results can be reconciled with previous observations
[22,24,43,44] to suggest a model for the role of lipid membranes in
the regulation of the complex (Fig. 6). Modelling suggests that the
transmembrane domain of PLB can ﬁt into a groove formed by
transmembrane helices M4, M6 and M9 of SERCA, allowing K3 in the
PLB cytoplasmic domain to extend up toward K397 and K400 in the
SERCA cytoplasmic domain some 15–20 Å away from the membrane
surface [45]. NMR measurements identiﬁed a number of “hot-spots”
in the cytoplasmic domain, including basic residues K3, R9, R13 and
R14, for which peaks double or disappear in the presence of SERCA,
consistent with these residues forming a binding interface with the
enzyme [22]. The SERCA-bound and free forms of PLB may therefore
have the cytoplasmic domain equilibrium displaced toward either of
two extreme (i.e., upright and horizontal) orientations. Interactions
between the N-terminal basic residues of PLB and the membrane
surface may reduce the propensity of the PLB cytoplasmic domain to
adopt the upright orientation necessary to interact with SERCA. In
membranes containing only zwitterionic lipids such as DOPC, it is
proposed that the dynamic equilibrium is inﬂuenced only weakly by
the membrane surface (Fig. 6a), but in membranes such as DMPC/
DOPG, which have a negative surface charge, the equilibrium is biased
further toward a membrane-associated orientation (Fig. 6b). As a
result, the fraction of PLB molecules with the cytoplasmic domain in
the correct orientation to come into contact with the SERCA
cytoplasmic domain is diminished and hence less PLB is available to
inhibit the enzyme.
5. Conclusions
It is well established that the phospholipid composition of
eukaryotic biomembranes changes with development, diet and
disease [46–48]. For example, in diets rich in ﬁsh oils the SR mem-
brane adapts to contains less anionic lipids PI and PS. It is thus
conceivable that the proportion of anionic lipids in the SR membrane
also has an indirect effect on SERCA function mediated by the pro-
pensity of the cytoplasmic domain of PLB to interact with the SR
membrane surface. Moreover, phosphorylation of PLB, which
increases calcium uptake by the SR necessary for muscle relaxation,
is associated with partial relief of SERCA inhibition. In the context of
the model proposed in Fig. 6, phosphorylation may also alter the
orientational equilibrium of the cytoplasmic domain between the
SERCA- and membrane-associated extremes.
The interaction between PLB in the cytoplasmic domain and
anionic phospholipids raises further questions. The lipid composition
of membranes can modulate the function of SERCA enzymes directly,
and ATPase activity in bilayers of phosphatidylcholine and anionic
phosphatidylserine or phosphatidic acid becomes lower as the
fraction of negatively charged lipid increases [49]. Our earlier work
suggested that PLB1–23 may bind anionic lipids and sequester them
into localised clusters, leaving behind pools of predominantly
zwitterionic lipids [25]. This raises the intriguing possibility that PLB
could inﬂuence the local distribution of lipids surrounding SERCA andinﬂuence enzyme activity via a secondary mechanism. Moreover, it is
noted that most structural studies of PLB using NMR spectroscopy
have examined the protein solubilised in micelles of dodecylpho-
sphocholine or incorporated into phosphatidylcholine bilayers, both
of which have zwitterionic head groups [50–52]. In the absence of a
net surface charge, the micelles and membranes do not necessarily
reﬂect the SR lipid environment and consequently interactions of the
PLB cytoplasmic domain with the membrane surface are likely to be
weak. By showing that the inhibitory effect of PLB is affected by
membrane surface charge, this work draws attention to lipid
composition as a consideration when drawing conclusions about the
structure–function relationship of PLB in vitro.
These results provide motivation for further structural studies of
full-length, membrane embedded PLB to investigate the physiological
role of the lipid membrane in modulating interactions with SERCA.
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